VRE and VSE bacteremia outcomes in the era of effective VRE therapy: A systematic review and meta-analysis

Infection Control and Hospital Epidemiology

Volumn 37, Issue 1, 2016, Pages 26-35

  Prematunge, Chatura ^a   MacDougall, Colin ^a   Johnstone, Jennie ^a,b,c   Adomako, Kwaku ^a   Lam, Freda ^a   Robertson, Jennifer ^a   Garber, Gary ^a,c,d,e  

^a PUBLIC HEALTH ONTARIO   (Canada)

^b ST JOSEPH S HEALTH CENTRE   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF OTTAWA   (Canada)

^e OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BACTEREMIA; CASE CONTROL STUDY; COHORT ANALYSIS; CONFERENCE PAPER; ENTEROCOCCUS; HOSPITAL MORTALITY; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; LENGTH OF STAY; META ANALYSIS; NONHUMAN; SYSTEMATIC REVIEW; VANCOMYCIN RESISTANT ENTEROCOCCUS; VANCOMYCIN SENSITIVE ENTEROCOCCUS; VARIANCE; GRAM-POSITIVE BACTERIAL INFECTIONS; MICROBIOLOGY; MORTALITY; TREATMENT OUTCOME;

ANTIINFECTIVE AGENT;

ANTI-BACTERIAL AGENTS; BACTEREMIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HOSPITAL MORTALITY; HUMANS; LENGTH OF STAY; TREATMENT OUTCOME; VANCOMYCIN-RESISTANT ENTEROCOCCI;

EID: 85017136160     PISSN: 0899823X     EISSN: 15596834     Source Type: Journal    
DOI: 10.1017/ice.2015.228     Document Type: Conference Paper

References (28)

1. Cetinkaya Y, Falk P, Mayhall CG. Vancomycin-resistant enterococci. Clin Microbiol Rev 2000;13:686-707.
2. Murray BE. Vancomycin-resistant enterococcal infections. N Engl J Med 2000;342:710-721.
3. Ramsey AM, Zilberberg MD. Secular trends of hospitalization with vancomycin-resistant Enterococcus infection in the United States, 2000-2006. Infect Control Hosp Epidemiol 2009; 30:184-186.
4. Gravel D, Archibald CP, Pelude L, Mulvey M, Golding G. Antimicrobial resistance surveillance in Canadian hospitals, 2007-2012. Canada Communicable Disease Report CCDR 2014, Volume 40:November 21, 2014. 40 S-40 2; Accessed November 21, 2014.
5. Salgado CD, Farr BM. Outcomes associated with vancomycinresistant enterococci: a meta-analysis. Infect Control Hosp Epidemiol 2003;24:690-698.
6. DiazGranados CA, Jernigan JA. Impact of vancomycin resistance on mortality among patients with neutropenia and enterococcal bloodstream infection. J Infect Dis 2005;191:588-595.
7. Erlandson KM, Sun J, Iwen PC, Rupp ME. Impact of the more-potent antibiotics quinupristin-dalfopristin and linezolid on outcome measure of patients with vancomycin-resistant Enterococcus bacteremia. Clin Infect Dis 2008;46:30-36.
8. Balli EP, Venetis CA, Miyakis S. Systematic review and meta-analysis of linezolid versus daptomycin for treatment of vancomycin-resistant enterococcal bacteremia. Antimicrob Agents Chemother 2014;58:734-739.
9. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009;339:b2535.
10. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 ed. The Cochrane Collaboration; 2011.
11. Linden PK. Treatment options for vancomycin-resistant enterococcal infections. Drugs 2002;62:425-441.
12. Moher D, Pham B, Lawson ML, Klassen TP. The inclusion of reports of randomised trials published in languages other than English in systematic reviews. Health Technol Assess 2003; 7:1-90.
13. Wells GA, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. Ottawa hospital Research Institute Website. http://www.ohri.ca/programs/clinical-epidemiology/oxford.asp. Published 2014. Accessed April, 20, 2015.
14. Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 2005;5:13.
15. Bar K, Wisplinghoff H, Wenzel RP, Bearman GM, Edmond MB. Systemic inflammatory response syndrome in adult patients with nosocomial bloodstream infections due to enterococci. BMC Infect Dis 2006;6:145.
16. Billington EO, Phang SH, Gregson DB, et al. Incidence, risk factors, and outcomes for Enterococcus spp. blood stream infections: a population-based study. Int J Infect Dis 2014;26: 76-82.
17. Butler AM, Olsen MA, Merz LR, et al. Attributable costs of enterococcal bloodstream infections in a nonsurgical hospital cohort. Infect Control Hosp Epidemiol 2010;31:28-35.
18. Cheah AL, Spelman T, Liew D, et al. Enterococcal bacteraemia: factors influencing mortality, length of stay and costs of hospitalization. Clin Microbiol Infect 2013;19:E181-E189.
19. Cho SY, Lee DG, Choi SM, et al. Impact of vancomycin resistance on mortality in neutropenic patients with enterococcal bloodstream infection: a retrospective study. BMC Infect Dis 2013;13:504.
20. Haas EJ, Zaoutis TE, Prasad P, Li M, Coffin SE. Risk factors and outcomes for vancomycin-resistant Enterococcus bloodstream infection in children. Infect Control Hosp Epidemiol 2010;31: 1038-1042.
21. Marschall J, Piccirillo ML, Fraser VJ, Doherty JA, Warren DK. Catheter removal versus retention in the management of catheter-associated enterococcal bloodstream infections. Can J Infect Dis Med Microbiol 2013;24:e83-e87.
22. Mikulska M, Del Bono V, Raiola AM, et al. Enterococcal bloodstream infection after hematopoietic stem cell transplant: experience of a center with a low prevalence of vancomycine8resistant enterococci. Clin Infect Dis 2012;55:1744.
23. Mohr JF, Friedrich LV, Yankelev S, Lamp KC. Daptomycin for the treatment of enterococcal bacteraemia: results from the Cubicin Outcomes Registry and Experience (CORE). Int J Antimicrob Agents 2009;33:543-548.
24. Peel T, Cheng AC, Spelman T, Huysmans M, Spelman D. Differing risk factors for vancomycin-resistant and vancomycinsensitive enterococcal bacteraemia. Clin Microbiol Infect 2012; 18:388-394.
25. Vydra J, Shanley RM, George I, et al. Enterococcal bacteremia is associated with increased risk of mortality in recipients of allogeneic hematopoietic stem cell transplantation. Clin Infect Dis 2012;55:764-770.
26. Yoo JH, Lee DG, Choi SM, et al. Vancomycin-resistant enterococcal bacteremia in a hematology unit: molecular epidemiology and analysis of clinical course. J Korean Med Sci 2005;20: 169-176.
27. da Silva NS, Muniz VD, Estofolete CF, Furtado GH, Rubio FG. Identification of temporal clusters and risk factors of bacteremia by nosocomial vancomycin-resistant enterococci. Am J Infect Control 2014;42:389-392.
28. Cheah AL, Peel T, Howden BP, et al. Case-case-control study on factors associated with vanB vancomycin-resistant and vancomycin-susceptible enterococcal bacteraemia. BMC Infect Dis 2014;14:353.